Zantac Recall Notification

September 27, 2019

Dear AAAI patient,

Our records indicate that you may have been prescribed or recommended to take Zantac or its generic equivalent Ranitidine in the past. The FDA is currently investigating these two medications for potentially containing low levels of a possible cancer causing substance, NDMA. While the FDA has not required Zantac be taken off the market, we suggest you contact our office with any concerns. As a precaution, it is likely that our physicians will recommend a switch to Pepcid (Famotidine) or Tagamet (Cimetidine), which are similar medications and have not been reported to contain NDMA. We encourage you to contact our office with questions.

The FDA posts recalls on their website. The lots reported to date are from the manufacturer Apotex. Additional information about the voluntary recall can be found in the FDA announcement at the weblink listed below:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and?utm_campaign=Apotex%20Corp.%20Issues%20Voluntary%20Nationwide%20Recall%20of%20Ranitidine%20Tablets%2075mg%20and%20150mg&utm_medium=email&utm_source=Eloqua

If you have any questions or concerns, please call our office at 602-843-2991.

Arizona Asthma and Allergy Institute